Table 3.
Length of inpatient stay associated with invasive aspergillosis.
| Author | Year | Study design | Study period | Country | Level of care | Population description (N) |
Number of patients with pathogen (N) |
Length of stay (days) |
|---|---|---|---|---|---|---|---|---|
| Lane et al.32 | 2018 | Retrospective cohort study Single center |
2010–2016 | USA | CH | Patients with positive fungal culture: (3929) Patients with positive Aspergillus cultures: (117/3929 [3%]) Chronic respiratory disease: (27/117 [23.1%]) Diagnosed with IPA: (33/117 [28.2%]) |
IPA cases cultured Aspergillus fumigatus: 26/33 (78.8%) |
In IPA cases Range: 21–532 days |
| Forsythe et al.33 | 2020 | Cross-sectional study | 2012–2017 | USA | NS | Patients with: aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis, para-coccidioidomycosis, sporotrichosis, chromoblastomycosis, phaeohyphomycosis. Patients who are otherwise healthy, aged >65 years, those receiving immunosuppressants, with cancer, post-transplantation, or with HIV infection |
SM: (33 230) Aspergillosis using ICD-10-CM codes: (37.7%) |
NS Hospitalizations significantly greater in patients with SM and, on immunosuppressant medications (36.9% [n = 5513] vs. 17.5% [ n = 4 166 383]) With cancer (50.2% [n = 3284] vs. 8.88% [n = 775 313]) Post-transplantation (74.5% [n = 1099] vs. 65.1% [n = 37 913]) With HIV infections (39.1% [n = 532] vs. 13.3% [n = 91 275]) |
N, number; USA, United States of America; CH, community hospital; IPA, invasive pulmonary aspergillosis; NS, not stated; SM, systemic mycoses; ICD-10-CM, International Classification of Diseases-Tenth Revision-Clinical Modification; and HIV, human immunodeficiency virus.